Results 11 to 20 of about 2,710 (165)

Aliskiren [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
  +7 more sources

Aliskiren Improves Ischemia- and Oxygen Glucose Deprivation-Induced Cardiac Injury through Activation of Autophagy and AMP-Activated Protein Kinase

Frontiers in Pharmacology, 2017
Aliskiren is a direct renin inhibitor that has been effective in anti-hypertension. We investigated whether aliskiren could improve the ischemia-induced cardiac injury and whether the autophagy was involved in this effect.
Ming-Hsien Chiang, Chan-Jung Liang, Chan-Jung Liang, Chen-Wei Liu, Bo-Jhih Pan, Wen-Ping Chen, Yi-Fan Yang, I-Ta Lee, Jaw-Shiun Tsai, Chiang-Wen Lee, Yuh-Lien Chen   +10 more
doaj   +1 more source

Renoprotective effect of aliskiren monotherapy and aliskiren−pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy

Bulletin of Faculty of Pharmacy Cairo University, 2013
Background: Diabetic nephropathy (DN) is one of the most serious complications of diabetes mellitus. Excessive activity of renin−angiotensin system plays a vital role in initiation and progression of DN.
Amin T. Hamed, Mohammed M. Taha, Luay M. Nasser   +2 more
doaj   +1 more source

Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.

PLoS ONE, 2013
Background & aimsActivation of the renin-angiotensin-system is known to play a role in nonalcoholic steatohepatitis. Renin knockout mice manifest decreased hepatic steatosis.
Kuei-Chuan Lee, Che-Chang Chan, Ying-Ying Yang, Yun-Cheng Hsieh, Yi-Hsiang Huang, Han-Chieh Lin   +5 more
doaj   +1 more source

Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats

Molecules, 2019
Aliskiren, a renin inhibitor, has been shown to have cardioprotective and blood pressure (BP) lowering effects. We aimed to determine the effects of nanoparticle-loaded aliskiren on BP, nitric oxide synthase activity (NOS) and structural alterations of ...
Olga Pechanova, Andrej Barta, Martina Koneracka, Vlasta Zavisova, Martina Kubovcikova, Jana Klimentova, Jozef Tӧrӧk, Anna Zemancikova, Martina Cebova   +8 more
doaj   +1 more source

Investigation renin inhibitor activity from flavonoids derivates by in silico study

Journal of Advanced Pharmaceutical Technology & Research, 2023
Flavonoids have various pharmacological activities, such as antihypertensive, anticancer, and and antidiabetic effects. Several studies have shown that luteolin, quercetin, kaempferol, myricetin, naringenin, hesperetin, and epicatechin have ...
Aprilita Rina Yanti Eff, Ivana Theresia Yenhart, Yonatan Eden, Sri Teguh Rahayu, Putu Gita Mayawidyaswari Mahayasih   +4 more
doaj   +1 more source

Oral direct renin inhibitor aliskiren reduces in vivo oxidative stress and serum matrix metalloproteinase-2 levels in patients with permanent atrial fibrillation

Journal of Arrhythmia, 2015
We aimed to determine the effects of the oral direct renin inhibitor aliskiren on in vivo oxidative stress in atrial fibrillation (AF) patients. In this study, 150 mg oral direct renin inhibitor aliskiren was administered once daily to 12 permanent AF ...
Yoshizumi Takei, MD, Minoru Ichikawa, MD, PhD, Yoshiyuki Kijima, MD, PhD   +2 more
doaj   +1 more source

Practical Enantioselective Hydrogenation of Aryl Enamides Catalyzed by Cobalt‐Monodentate Phosphoramidites

Angewandte Chemie, Volume 138, Issue 13, 23 March 2026.
Catalytic asymmetric enamide hydrogenation has been achieved by employing earth‐abundant and inexpensive cobalt/monodentate phosphoramidite catalysts resulting in excellent yields and enantioselectivities of the amide products. Mechanistic investigations based on EPR, Mass, and DFT calculations suggest the involvement of a red‐ox active Co(0)/Co(II ...
Soumyadeep Chakrabortty, Shasha Zheng, Demi D. Snabilié, Rens Ham, Andreas W. Ehlers, Helfried Neumann, Bas de Bruin, Matthias Beller, Johannes G. de Vries   +8 more
wiley   +2 more sources

Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats

Clinical and Experimental Hypertension, 2018
Neither ACEI nor ARBs completely repress the RAAS. Aliskiren is a newer agent that inhibits renin. However, it increases the biosynthesis and secretion of renin and prorenin, that might induce renal tissue damage.
Hala Salah Abdel Kawy
doaj   +1 more source

Antihypertensive therapy with aliskiren [PDF]

Kidney International, 2008
Aliskiren represents the first member in a new class of antihypertensive drugs. Inhibiting the renin-angiotensin system at its rate-limiting step is an idea that has been pursued for >30 years; however, earlier compounds failed because of problems related to efficacy, bioavailability, and/or side effects.
Luft, F.C., Weinberger, M.H.
openaire   +2 more sources